

**MEETING MINUTES
OF THE
CENTERS FOR MEDICARE AND MEDICAID SERVICES
MEDICARE EVIDENCE DEVELOPMENT & COVERAGE
ADVISORY COMMITTEE**

September 22, 2021

**Centers for Medicare and Medicaid Services
7500 Security Boulevard
Baltimore, Maryland**

Medicare Evidence Development & Coverage Advisory Committee

September 22, 2021

Attendees (Remotely)

Committee Chair

Peter Bach, MD, MAPP

Committee Vice-Chair

Joseph Ross, MD, MHS

MedCAC Members

Cecelia C. Brewington, MD

Michael P. Cinquegrani, MD

Ella Annabelle Effat Kazerooni, MD, MS

Stephen Lahey, MD

Brian J. Miller, MD, MBA, MPH

Alan Speir, MD

Allison Stephens

Gregory Thomas, MD, MPH, FACC, MASNC

Sam Tyagi, MD

Steven Waldren, MD

CMS Liaison

Joseph Chin, MD

Invited Guest Speakers

Sameer A. Ansari, MD, PhD

Walter Koroshetz, MD

Jeffrey L. Saver, MD

Adnan H. Siddiqui, MD, PhD, FACS, FAHA

MEDCAC Coordinator

Tara Hall

Wednesday, September 22, 2021, 8:00 a.m. EDT

The Medicare Evidence Development & Coverage Advisory Committee met virtually via Zoom on September 22, 2021, to discuss health outcomes in cerebral vascular disease treatment studies.

The meeting began with a reading of a conflict of interest statement, welcoming remarks, and an introduction of the Committee.

CMS Presentation. A CMS representative presented information summarizing the specific factors of interest to CMS in this meeting, in order to provide clarity and transparency in IDE and National Coverage Analyses for the cerebrovascular disease treatment technologies. He then presented the voting questions to the panel.

Presentations by Invited Guest Speakers. The panel heard presentations from the invited guest speakers. Dr. Koroshetz gave the panel an introduction to stroke categories, causes and assessment measure relevant to the questions before the panel. Dr. Saver spoke on distinctive aspects of outcome assessment in neurovascular disease, focusing on acute stroke, utility of different scales used to assess stroke recovery and prevention. Dr. Ansari presented an overview of the use of registries to evaluate effectiveness of stroke assessment, treatment and recovery trials. Dr. Siddiqui encouraged the panel to carefully consider existing evidence for stroke assessment and treatment.

Scheduled Public Comments. The panel heard from a total of four scheduled speakers, presenting the consensus opinions of multiple professional societies in the stroke space.

Questions to Presenters. The panel participated in a lengthy discussion and question and answer session with all of the presenters, which is recorded in the transcript.

Initial Open Panel Discussion, Formal Remarks and Voting Questions. The panel conducted an in depth discussion of the issues raised, before turning its attention to the voting questions. During the voting, each panelist announced his or her vote, and provided reasoning for the vote. For those questions receiving a mean vote of intermediate confidence (2.5) or greater, the discussion questions were also addressed.

Final Open Panel Discussion. At the conclusion of voting and discussion questions, each panel member was given the opportunity to give final comments on topics covered, including recommended next steps.

Closing Remarks. Dr. Chin and Dr. Bach extended thanks to the panelists, presenters and public for participating in the meeting.

Adjournment. The meeting adjourned at 4:18 p.m. EDT.

I certify that I attended the meeting
of the Medicare Evidence Development
and Coverage Advisory Committee on
September 22, 2021, and that these minutes
accurately reflect what transpired.

X Tara Hall

Tara Hall
MEDCAC Coordinator, CMS

I approve the minutes of this meeting
as recorded in this summary.



Peter Bach, MD, MAPP
MEDCAC Chair